YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Kiniksa Pharmaceuticals International (KNSA) has drawn fresh attention after recent share performance data highlighted sharp swings, with the stock down about 4% over the past month but up roughly 34% in the past 3 months. Short term momen…
Shares of Kiniksa Pharmaceuticals International KNSA have soared 41% over the past three months, driven by strong sales growth from its leading commercial product, Arcalyst, upward revisions to the company's 2026 revenue outlook and encour…
Biotech leader Kiniksa stock is poised to hit a fresh buy point after shares soared 25% in response to better-than-expected sales numbers. Continue Reading
Kiniksa Pharmaceuticals International, Plc LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Ann…
Biotech stock TG Therapeutics is building a cup base after a sell-off in early August. It is testing a key moving average. Continue Reading
These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months. Continue Reading
Sales of Kiniksa Pharmaceuticals' biggest product, Arcalyst, are expected to begin declining in 2030. But the company has a plan. Continue Reading
Kiniksa Pharmaceuticals International, Plc LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46t…
LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, Au…
Kiniksa Pharmaceuticals International, plc KNSA used its second-quarter 2026 earnings call to emphasize accelerating ARCALYST adoption and a higher full-year sales outlook. Management also moved KPL-387 into pivotal testing, adding a secon…
Madrigal Pharmaceuticals MDGL reported second-quarter 2026 loss of $1.99 per share, narrower than the Zacks Consensus Estimate of a loss of $2.55. In the same quarter last year, the company had incurred a loss of $1.50 per share. In the se…
Teva Pharmaceutical Industries Limited TEVA reported second-quarter 2026 adjusted earnings of 2 cents per share, which missed the Zacks Consensus Estimate of 8 cents. Adjusted earnings declined 97% year over year due to higher acquisition…
Kiniksa Pharmaceuticals International, plc (KNSA) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts stil…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Kiniksa Pharmaceuticals International (KNSA) just raised its 2026 n…
Kiniksa Pharmaceuticals International, plc recently reported its second-quarter 2026 results, with revenue rising to US$243.6 million and net income to US$25.43 million, and it raised full-year 2026 net product revenue guidance to a range…
(RTTNews) - Today's top biotech gainers include Trinity Biotech, which recently completed reverse split; OPKO Health, driven by its second-quarter financial results and continued pipeline progress; Kiniksa Pharma, after raising its revenue…
Alkermes plc ALKS reported break-even earnings for the second quarter of 2026 against the Zacks Consensus Estimate of a loss of 4 cents per share. The company had recorded earnings of 52 cents per share in the year-ago quarter. During the…
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.3 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.23 per share a year ago. These figures are adjusted for non-r…
Kiniksa Pharmaceuticals International, Plc – ARCALYST® (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $980 - $995 million – –…
– ARCALYST¨ (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $980 - $995 million – – KPL-387 Phase 2 data demonstrated rapid and…
Major earnings expected before the bell on Tuesday include: * PayPal Holdings (PYPL [https://seekingalpha.com/symbol/PYPL]) * The Coca-Cola Company (KO [https://seekingalpha.com/symbol/KO]) * The Boeing Company (BA [https://seekingalpha.co…
AstraZeneca AZN announced that the European Commission (EC) has approved Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for the first-line treatment of a certain type of breast cancer. The EC approved Etcamah in combination…
For Immediate Release Chicago, IL – July 24, 2026 – Stocks in this week's article are American Outdoor Brands Inc. AOUT, Cimpress plc CMPR, National Energy Services Reunited Corp. NESR, CTO Realty Growth Inc. CTO and Kiniksa Pharmaceutical…
Kiniksa Pharmaceuticals International, Plc LONDON, July 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 28, 2026 a…
Pfizer PFE announced that the FDA has accepted the supplemental new drug application (sNDA) for Talzenna (talazoparib), an oral PARP inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor (ARPI), for a…
Community Health Systems, Inc. CYH reported a second-quarter 2026 net loss of 19 cents per share, missing the Zacks Consensus Estimate of a loss of 18 cents. The bottom line deteriorated significantly from a loss of 5 cents per share in th…
Repligen Corporation RGEN announced that it has entered into a definitive agreement to acquire Washington-based BioLife Solutions BLFS, a leading developer of bioproduction products and services, for a total value of approximately $1.5 bil…
The astonishing rally of the artificial intelligence (AI) trade has been suffering from persistent volatility over the past month. Extremely overstretched valuation of these stocks, unabated inflationary pressure due to fluctuations in cru…
Nektar Therapeutics NKTR announced that it has initiated the first two registrational studies in the phase III ZENITH AD program, which is evaluating its pipeline candidate, rezpegaldesleukin (rezpeg), for treating moderate-to-severe atopi…
Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. The tren…
Eli Lilly LLY announced that it has entered into a definitive agreement to acquire New York-based clinical-stage biotech AtaiBeckley ATAI for an initial upfront payment of $2.8 billion. Shares of ATAI were up 33.4% yesterday following the…
UnitedHealth Group Incorporated UNH reported second-quarter 2026 adjusted earnings per share (EPS) of $6.38, which beat the Zacks Consensus Estimate of $4.94. The bottom line rose 56.4% year over year. Revenues rose 0.4% year over year to…
Shares of clinical-stage company AtaiBeckley ATAI surged 63.3% in after-hours trading on Wednesday after a Bloomberg report stated, citing people familiar with the matter, that pharma bigwig Eli Lilly LLY is in discussions for a potential…
AstraZeneca AZN announced that it has entered into an exclusive license agreement with China-based pharmaceutical company Dizal Pharmaceutical to acquire worldwide rights to develop and commercialize the latter's lung cancer drug, Zegfrovy…
Investors prefer to invest in businesses that reap profits on a regular basis. To gauge the extent of profits, there is no better metric than the net profit margin. A higher net margin reflects a company's efficiency in converting sales in…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. What Kiniksa's Index Additions Mean For Investors Kiniksa Pharmaceuticals International (KNSA) has…